report on telomere-targeted treatment with imetelstat in 18 patients with essential thrombocythemia. The drug was effective in controlling platelet levels in all patients, albeit often at the expense of hemoglobin and neutrophil levels. However, the other main treatment goals in essential thrombocythemia 2 -controlling symptoms and preventing both disease progression and thromboembolic complications -were definitely not achieved. Fatigue, diarrhea, and nausea were all reported by more than 70% of the patients. A total of 3 patients had progression to myelofibrosis, and 2 patients had a thromboembolic event. Thus, treatment with imetelstat does not seem to be promising in this relatively benign disease.
Only 4 patients had received interferon before undergoing this experimental therapy. Pegylated interferon alfa-2 is effective in controlling thrombocytosis in most patients, and it is not associated with myelofibrotic transformation, leukemogenicity, or other adverse long-term events. 3 Furthermore, interferon may induce a deep molecular remission (i.e., a very low JAK2 V617F mutation level) and normalization of bone marrow changes, effects that in some patients may be maintained years after treatment cessation. 3, 4 In Denmark, interferon is suggested as first-line treatment in patients with essential thrombocythemia. 1 Armanios and Greider 2 suggest that the experimental drug imetelstat may change the natural course of myeloproliferative neoplasms, possibly by binding to cell-surface receptors such as toll-like receptor 9 (TLR9). Since TLR9 induces the production of type I interferons by plasmacytoid dendritic cells, 3 it is tempting to speculate that the effect may be mediated through interferon alfa-2, which in several studies during the past 25 years has proved to be highly effective and safe in the treatment of myeloproliferative neoplasms with the induction of complete hema- tologic remission. 4 In a subgroup of patients, deep molecular remissions with a reduction in JAK2 V617F mutant alleles and normalization of the bone marrow were sustained even years after the discontinuation of interferon alfa-2, findings that are compatible with "minimal residual disease."
5 Thus, interferon alfa-2 may change the natural course of myeloproliferative neoplasms if the drug is initiated at the time of diagnosis. 4 Given the toxic side effects and modest treatment response associated with imetelstat, we do not think this drug can be considered as an alternative to interferon alfa-2, which in addition to its immune-modulating effects is a telomerase inhibitor as well. 
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Dr. Baerlocher and colleagues reply: Our phase 2 study of imetelstat enrolled 18 patients with essential thrombocythemia with a median interval of 7 years since initial diagnosis. All the patients had received a median of two previous therapies, including hydroxyurea, anagrelide, and interferon. Although interferon is used in patients with essential thrombocythemia, this disorder is not an approved indication. A total of 4 patients in our study were previously treated with interferon; 1 had resistance, and 3 had unacceptable side effects. All 4 of these patients had a hematologic response to imetelstat, and 2 of the 3 patients with mutations had a molecular response.
Rapid, substantial hematologic and molecular responses that were observed in such patients provided evidence of anticlonal activity and proof-of-concept data for further investigation of imetelstat in patients with advanced myeloid cancers. The interpretation of data with respect to progression to myelofibrosis and thromboembolic events in patients with long treatment histories is difficult from this single-group study. Since publication of their article, the authors report no further potential conflict of interest.
Dr. Tefferi replies: It is true that imetelstat may not have the side-effect profile that justifies its further consideration for the treatment of essential thrombocythemia, as reported by Baerlocher et al. However, drug benefit-risk assessment is best accomplished in the context of randomized studies and should not be surmised from the results of a small proof-of-concept study. The same holds true for other drugs for the treatment of essential thrombocythemia, including interferon alfa. Treatment-induced reduction in the JAK2 or CALR mutant allele burden in patients with essential thrombocythemia has been observed with imetelstat, interferon alfa, 1 and busulfan. Such observations do not necessarily imply that each of these drugs has the same effect on coexistent disease clones with different mutations 3 or an advantage in terms of meaningful health outcome; the latter requires evidence from controlled studies and not conjecture based on local treat-
